Clinical Research Directory
Browse clinical research sites, groups, and studies.
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
Sponsor: Johns Hopkins University
Summary
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Official title: Assessing the Modulation of Retinal Atrophy and Neurofilament Light Chain by Ofatumumab in Relapsing Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
75
Start Date
2023-05-22
Completion Date
2027-03
Last Updated
2025-06-06
Healthy Volunteers
No
Interventions
Ofatumumab
Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study
Locations (1)
Johns Hopkins
Baltimore, Maryland, United States